This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice
by Zacks Equity Research
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
ICU Medical (ICUI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Match Group (MTCH) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Match Group (MTCH) boasts of a robust product portfolio comprising Tinder, Match.com, Meetic, PlentyOfFish and OkCupid.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
Why the Earnings Surprise Streak Could Continue for ICU Medical (ICUI)
by Zacks Equity Research
ICU Medical (ICUI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
TG Therapeutics (TGTX) shares rose nearly 9% in the last trading session, amid huge volumes.
ICU Medical (ICUI) Enters Oversold Territory
by Zacks Equity Research
ICU Medical, Inc. (ICUI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
Medical - Products Stock Outlook: Short-Term Pain Inevitable
by Zacks Equity Research
Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Why ICU Medical (ICUI) Might be Well Poised for a Surge
by Zacks Equity Research
ICU Medical (ICUI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
5 Momentum Stocks Worth Investing in via Driehaus Strategy
by Zacks Equity Research
Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.
ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 45.36% and 7.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is ICU Medical (ICUI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is ICU Medical, Inc. (ICUI) Outperforming Other Medical Stocks This Year?
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
by Zacks Equity Research
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
Shrug Off Market Volatility With These 5 Low Beta Stocks
by Zacks Equity Research
We develop a strategy that clearly shows that less risky stocks have the potential to reward shareholders with impressive returns only when certain parameters are considered.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural